Baseline HIV genotypic resistance testing in patients newly diagnosed with HIV : When do we need to consider baseline integrase resistance testing for everyone?
- 22 October 2026
- journal article
- Published by Wiley in HIV Medicine
Abstract
Background: We aimed to describe baseline drug resistance in patients newly diagnosed with HIV in Brighton over a 12‐year period. Method: As part of a quality improvement project, clinic data were collected for all patients newly diagnosed with HIV between January 2014 and December 2025. Locally, baseline genotypic resistance testing is routinely performed at diagnosis and assessed for resistance to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). Since 2022, baseline resistance for integrase inhibitors (INIs) has also been performed. Transmitted drug resistance mutations for NRTIs, NNRTIs and PIs were defined according to the World Health Organization (WHO) criteria. Integrase resistance mutations were identified using the Stanford HIV Drug Resistance Database. Extracted data included patient demographics, date of HIV diagnosis, HIV subtype and previous HIV pre‐exposure prophylaxis (HIV‐PrEP) use. Results: Three hundred and eighteen individuals newly diagnosed with HIV throughout the study period, of which 312 had a resistance report available for analysis. Overall, baseline drug resistance was found in 38/312 (12%, 95% CI 8.76–16.33). The median age was 37 years (IQR 30–46). 13 (39%) patients were non‐UK born and 17 (52%) had a non‐B subtype. There were 12 (4%) individuals with NRTI resistance mutations, 13 (4%) with NNRTI mutations and 5 (2%) with PI mutations. Integrase resistance mutations were found in 8/73 (11%) between 2022 and 2025, 3 of whom had no other class resistance. Baseline drug resistance was associated with non‐clade B genotypes (OR = 2.79, 95%CI = 1.34–5.79, p = 0.006) and previous HIV‐PrEP use (OR = 4.14, 95%CI = 1.66–10.4, p = 0.003). Conclusion: This manuscript identified a number of cases where baseline integrase resistance was identified. These data suggest that more work is needed to establish whether baseline integrase inhibitor resistance testing is warranted in all individuals newly diagnosed with HIV.Keywords
This publication has 9 references indexed in Scilit:
- Driving progress towards PrEP equity: Key changes in the 2025 BASHH/BHIVA UK PrEP guidelinesHIV Medicine, 2025
- BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022HIV Medicine, 2022
- How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?Current Opinion in HIV and AIDS, 2022
- Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) studyHIV Medicine, 2020
- HIV-1 transmitted drug resistance in Brighton, UK, from 2014 to 2020International Journal of STD & AIDS, 2020
- Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistanceJournal of Antimicrobial Chemotherapy, 2019
- Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UKJournal of Antimicrobial Chemotherapy, 2016
- Recent trends and patterns in HIV‐1 transmitted drug resistance in the United KingdomHIV Medicine, 2016
- Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 UpdatePLOS ONE, 2009